Synthesis and structure−activity relationship of 8-substituted protoberberine derivatives as a novel class of antitubercular agents by unknown
Li et al. Chemistry Central Journal 2013, 7:117
http://journal.chemistrycentral.com/content/7/1/117RESEARCH ARTICLE Open AccessSynthesis and structure−activity relationship of
8-substituted protoberberine derivatives as a
novel class of antitubercular agents
Ying-Hong Li1†, Hai-Gen Fu1†, Feng Su2, Li-Mei Gao1, Sheng Tang1, Chong-Wen Bi1, Yu-Huan Li1,
Yan-Xiang Wang1* and Dan-Qing Song1*Abstract
Background: The emergence of multi-drug resistant tuberculosis (MDR-TB) has heightened the need for new
chemical classes and innovative strategies to tackle TB infections. It is urgent to discover new classes of molecules
without cross-resistance with currently used antimycobacterial drugs.
Results: Eighteen new 8-substituted protoberberine derivatives were synthesized and evaluated for their
anti-mycobacterial activities against Mycobacterium tuberculosis (M. tuberculosis) strain H37Rv. Among them, compound
7g was the most effective antitubercular agent with minimum inhibitory concentration (MIC) of 0.5 μg/mL. Moreover,
it also afforded a potent antitubercular effect against clinically isolated MDR strains of M. tuberculosis with MICs ranging
from 0.25 to 1.0 μg/mL, suggesting a novel mode of action.
Conclusions: The structure−activity relationship (SAR) analysis revealed that introduction of a substituent at the
8-position in pseudoprotoberberine, especially an n-decyl, could significantly enhance the anti-TB activity. We
consider 8-n-decylberberines to be a novel family of anti-tubercular agents with an advantage of inhibiting MDR
strains of M. tuberculosis.
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Currently, one third of the world’s population is infected
with Mycobacterium tuberculosis (M. tuberculosis) [1]. It
is anticipated that there will be about 8.9−9.9 million
new and relapse tuberculosis (TB) cases this year, more
than in any other year in history [2,3]. The limited ef-
fectiveness and long-term treatment lead to poor patient
compliance, which often causes multi-drug resistant
(MDR) and extensively-drug-resistant (XDR). The emer-
gence of new cases, the increased incidence of MDR
strains of M. tuberculosis, the adverse effects of first-line
anti-TB drugs isoniazid (INH) and rifampin (RIF) [4,5],
and the increased incidence of TB associated with HIV
infections [6-8] have led to renewed research interest
in discovering novel anti-TB drugs. Especially, the* Correspondence: lionking_0421@hotmail.com; songdanqingsdq@hotmail.com
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reproduction in any medium, provided the oremergence of MDR-TB and of the virtually untreatable
MDR-TB has heightened the need for new chemical
class and innovative strategies to tackle TB infections.
However, truly novel antitubercular drugs other than
repurposed drugs have not been developed since the
1970s [9,10]. Though new anti-TB drug Bedaquiline was
just approved by FDA last year [11], there is still an urgent
need to discover new classes of molecules without cross-
resistance with currently used antimycobacterial drugs.
We have identified 13-substituted protoberberine deriv-
atives to be a novel family of anti-TB agents [12] with poor
solubility. The primary structure−activity relationship
(SAR) indicated that the berberine ring (BBR, 1, Figure 1)
might be beneficial for keeping good antitubercular acti-
vity. In our ongoing efforts to discovering new anti-TB
agents, we turned our SAR analysis on the substituents at
the 8-position of BBR derivatives, by which nitrogen ion
at the 7-position might be blocked by the 8-substituents
with bigger volume, thereby enhancing the solubility of. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 2 General structural formula of 8-substituted BBR
derivatives.
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http://journal.chemistrycentral.com/content/7/1/117this kind of compounds. Based on this strategy, several
8-substituted protoberberine derivatives (6a–e) were
designed, semi-synthesized and evaluated for their antimy-
cobacterial activity against M. tuberculosis strain H37Rv.
Furthermore, by replacing 1 with pseudoberberine
(2, Figure 1) or palmatine (3, Figure 1) core, two natural
products extracted from Chinese herb Huanglian, by
which a group of new 8-substituted pseudoberberine
(7a–h) or palmatine (8a–e) derivatives was generated
for testing. Herein, eighteen 8-substituted protoberbe-
rine derivatives (Figure 2) were designed and syn-




Eighteen target compounds were synthesized with com-
mercially available 1, 3 or 2 (synthesized in our laboratory)
[13,14] as the starting material as described in Scheme 1.
The Grignard reagents were first prepared with Mg turn-
ings and the corresponding alkyl and aryl iodide in abso-
lute ether under N2 protection. The key intermediates
dihydroberberine, dihydropseudoberberine or dihydropal-
matine (4) were obtained via nucleophilic substitution of
newly synthesized Grignard reagents with 1, 2 or 3 under
N2 protection, respectively [15,16]. Then, the intermediate
4 was oxidized using bromine as a oxidizing agent in
HOAc at refluxing temperature to yield the 8-substitutedberberine bromate 5, which was converted into the corre-
sponding chloride 6–8 with AgCl in MeOH at room
temperature. Finally, the desired products in series 6, 7 and
8 were purified by flash column chromatography using
methanol/dichloromethane as the gradient eluent with

















R1MgI / Et2O, N2
0 oC, 2 h
0.1N Br2/AcOH
120oC, 2 h, 81-87%
1-3 4
5 6a-e: R2= 2,3-OCH2O-,   R3= 9,10-dimethoxy;
7a-h: R2=2,3-dimethoxy, R3= 9,10-dimethoxy;
8a-e: R2=2,3-OCH2O-,    R3= 10,11-dimethoxy;
MeOH, 2 h, 89-93%
R1=PhOCH3, PhCH3, PhCl, 1-naphthyl, 
      n-C10H21, n-C12H25.
Scheme 1 The synthetic route of the target compounds.
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http://journal.chemistrycentral.com/content/7/1/117Biological activity and SAR analysis of 8-substituted
protoberberine derivatives for anti-mycobacterial activity
Our SAR strategy was first focused on the modifications
of the substituents at the 8-position in BBR. According
to our previous SAR results, several lipophilic groups in-
cluding p-methoxyphenyl (6a), m-methoxyphenyl (6b),
p-methylphenyl (6c), 1-naphthyl (6d) and n-decyl (6e)
were introduced into the 8-position aiming to improve
the cLogP value (Table 1), thereby enhancing the anti-
mycobacterial activity. Among these analogues, com-
pound 6e possessing an n-decyl afforded the hightest
antibacterial activity with a MIC of 2.0 μg/mL against
M. tuberculosis. The results supported that the increased
cLogP value might be helpful for enhancing the anti-TB
activity of this kind of compounds.
In order to further explore the influence of the BBR
core, a variety of lipophilic substituents were attached to
the 8-position of 2, by which the 8 new 8-substituted
pseudoberberine classes (7a−h) were generated for test-
ing. The results showed (Table 1) that the majority of
them (7b−h) exhibited potential anti-mycobacterial ac-
tivities with MICs ranging from 0.5 μg/mL to 2.0 μg/mL.
It seems that the 10,11-dimethoxy on the ring D would
be beneficial for their binding affinity to the target mo-
lecular. Compound 7g bearing an n-decyl afforded the
best anti-TB activity with a MIC of 0.5 μg/mL. Similarly,
the lipophilic side-chains were also introduced to the
same position in 3, and then 5 new 8-substituted
palmatine analogues (8a−e) were made. As expected,
compound 8e with an n-decyl at position 8 had the mostpotent activity with an MIC of 1.0 μg/mL. It was de-
duced that an n-decyl at the 8-position would improve
the anti-mycobacterial activity as regarding to this kind
of compounds. The pesudoberberine ring might be
beneficial for the antimycobacterial activity, and thus the
representative compounds in 7 series were chosen for
further investigation.
Anti-resistance TB effect of 7g and 7f
As compound 7g bearing an n-alkyl at position 8 pos-
sessed an excellent activity against drug-susceptible M.
tuberculosis strain H37Rv, it was selected to test the
anti-TB activity against MDR strains. In this experi-
ment, M. tuberculosis strains 87, 192, 262 and 266
isolated from the patient infected with tuberculosis in
China, were resistant to both RIF and INH. RIF and
INH showed a decreased activity against the drug-
resistant stains partially or completely with MIC ranges
between 2 and > 32 μg/mL (Table 2), while compound
7g afforded a potential effect against MDR strains with
comparable MIC ranges of 0.25−1 μg/mL. In addition,
compound 7f possessing an aromatic moiety at the 8-
position in 7 series afforded a moderate cLogP value
(cLogP = 1.60) and then was chosen to evaluate for the
drug-resistant strains as well. As described in Table 2,
7f showed an equivalent potency against the drug-
susceptible strain H37Rv and multidrug-resistance iso-
lates of M. tuberculosis strains 257, 373, 559 and 164
with a MIC range between 2 and 4 μg/mL as well. The
results indicated that 7g and 7f were effective for drug-
Table 1 SAR of 8-substituted protoberberine analogous against M. tuberculosis strain H37Rv
Compda R1 R2 R3 R4 R5 R6 MICb cLogPc
1 > 128 −0.77
2 128 −1.08
3 > 128 −0.77
6a PhOCH3-p OCH2O OCH3 OCH3 H 32 0.35
6b PhOCH3-m OCH2O OCH3 OCH3 H 16 0.35
6c PhCH3-p OCH2O OCH3 OCH3 H 16 0.93
6d 1-naphthyl OCH2O OCH3 OCH3 H 8 1.60
6e n-C10H21 OCH2O OCH3 OCH3 H 2 3.29
7a PhOCH3-p OCH2O H OCH3 OCH3 4 0.35
7b PhOCH3-m OCH2O H OCH3 OCH3 2 0.35
7c PhCH3-p OCH2O H OCH3 OCH3 2 0.93
7d PhCl-p OCH2O H OCH3 OCH3 1 1.14
7e PhCl-m OCH2O H OCH3 OCH3 2 1.14
7f 1-naphthyl OCH2O H OCH3 OCH3 2 1.60
7g n-C10H21 OCH2O H OCH3 OCH3 0.5 3.29
7h n-C12H25 OCH2O H OCH3 OCH3 1 4.35
8a PhOCH3-p OCH3 OCH3 OCH3 OCH3 H 16 0.04
8b PhOCH3-m OCH3 OCH3 OCH3 OCH3 H 16 0.04
8c PhCH3-p OCH3 OCH3 OCH3 OCH3 H 16 0.62
8d 1-naphthyl OCH3 OCH3 OCH3 OCH3 H 4 1.29
8e n-C10H21 OCH3 OCH3 OCH3 OCH3 H 1 2.98
RIF 0.0625 3.90
INH 0.0625 −1.12
a: General structural formular is shown in Figure 2.
b: MIC: minimum inhibitory concentration.
c: Chemoffice Ultra 11.0 (Cambridge office).
RIF: rifampin; INH: isoniazid.
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isolated from TB patients in China, suggesting a mode
of action different from currently used anti-TB drugs.
Cytotoxicity of 7g and 7f in Vero and MRC-5 cells
Both of compounds 7g and 7f were further tested their
cytotoxicity in African green monkey kidney (Vero) and
human lung fibroblast (MRC-5) cells with MTT assay.
Cytotoxicity activity was expressed with CC50 value, andTable 2 In vitro antitubercular activities of compounds 7f
and 7g against MDR strains of M. tuberculosisa
(MIC: μg/mL)
Compd 257/87 373/192 559/262 164/266 H37Rv
7fb 2 4 2 2 2
7gc 0.5 0.25 0.5 1 0.5
RIF > 32 > 32 > 32 > 32 0.0625
INH 2 4 2 2 0.0625
a: MDR strains were isolated from patients with tuberculosis in China.
b: MIC values against MDR strains 257, 373, 559 and 164.
c: MIC values against MDR strains 87, 192, 262 and 266.the selectivity index (SI), as an important therapeutic indi-
cation, was calculated as the ratio of CC50 to MIC value.
Anti-TB effect of compounds 7g and 7f was evaluated by
combining their MIC with SI values. As described in
Table 3, compound 7g showed a moderate SI value of 10.3
and 17.6 in Vero and MRC-5 cells, respectively.
Experimental
Instruments
Melting point (m.p.) was uncorrected and recorded on a
Mettler Toledo MP90 melting point apparatus. 1H NMRTable 3 Cytotoxicitya activities of compounds 7f and 7g
in Vero and MRC-5 cells
Compd Vero MRC-5
CC50 (ug/ml) SI
b CC50 (ug/ml) SI
7f 14.72 ± 2.02 7.37 10.18 ± 2.78 5.09
7g 5.15 ± 1.29 10.3 8.78 ± 0.48 17.6
a: Cytotoxic concentration required to inhibit Vero or MRC-5 cell growth
by 50%.
b: Selectivity index (SI) value equaled to CC50/MIC.
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http://journal.chemistrycentral.com/content/7/1/117and 13C NMR spectra were recorded on Varian 400 MHz
spectrometer. Chemical shift was reported relative to in-
ternal tetramethylsilane (δ 0.00 ppm) or (CD3)2SO (δ 2.50
ppm) for 1H and (CD3)2SO (δ 39.5 ppm) for
13C. ESI
high-resolution mass spectra (HRMS) were recorded on
an Autospec UItima-TOF mass spectrometer (Micromass
UK Ltd, Manchester, UK). Flash chromatography was
performed on CombiflashRf 200 (Teledyne, Nebraska,
USA), particle size 0.038 mm.
General procedure to obtain final 8-substituted
protoberberine derivatives
Grignard reagents were prepared via Magnesium turnings
(3.8 g) with the corresponding alkyl and aryl iodides (0.13
mol) in absolute ether (100 mL) at 0°C. The synthesized
Grignard reagents were added to the suspension of dry 1,
2 or 3 (0.03 mol) in absolute ether (100 mL) dropwise
under N2 protection at 0°C [15,16]. After refluxing for 2 h,
saturated NH4Cl solution (200 mL) was added to quench
the reaction. The aqueous phase was extracted with ethyl
acetate (3 × 100 mL) and the combined organic layers
were washed with saturated brine (100 mL) and dried
(Na2SO4). The mixture was concentrated in vacuo to give
4. Then, bromine solution (1N/ HOAc, 30 mL) was added
to oxidize compound 4 in HOAc at refluxing temperature
to generate the 8-substituted BBR derivatives bromate 5,
which was treated with excessive AgCl in MeOH at room
temperature thus converted into the corresponding chlo-
ride form. Finally, the desired products in series 6, 7 and 8
were purified by flash column chromatography using
methanol/ dichloromethane as the gradient eluent with
overall yields of 72%–81%.
8-(p-Methoxy)phenylprotoberberine choride (6a)
Yield: 78%; Brown solid; mp 220–221°C; 1H NMR: δ 9.04
(s, 1H), 8.23 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 9.2 Hz, 1H),
7.84 (s,1H), 7.56 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz,
2H), 7.04 (s,1H), 6.18 (s,2H), 4.26 (t, J = 6.8 Hz, 2H), 4.00
(s, 3H), 3.98 (s, 3H), 3.20 (s, 3H), 3.01(t, J = 6.8 Hz, 2H);
13C NMR: δ 172.40, 160.65, 156.96, 153.08, 150.26, 148.18,
145.55, 138.47, 133.66, 131.30, 129.73, 126.90, 126.30,
124.72, 122.84, 121.88, 121.81, 114.41, 110.01, 108.36,
106.31, 102.56, 61.09, 57.44, 55.90, 52.26, 26.67; HRMS-




Yield: 79%; Orange solid; mp 206–207°C; 1H NMR: δ
9.07 (s, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 9.2 Hz,
1H), 7.85 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.20-7.26 (m,
3H), 7.04 (s, 1H), 6.18 (s, 2H), 4.27 (t, J = 6.4 Hz, 2H),
4.00 (s, 3H), 3.81 (s, 3H), 3.26 (s, 3H), 3.02 (t, J = 6.4 Hz,
2H); 13C NMR: δ 172.49, 159.61, 156.25, 153.02, 150.31,
148.20, 145.40, 138.37, 136.15, 133.72, 131.28, 130.41,126.41, 124.65, 122.44, 121.76, 120.09, 115.85, 113.70,
108.39, 106.29, 102.58, 61.15, 57.45, 55.87, 52.35, 26.66;




Yield: 76%; Orange solid; mp 158–160°C (decomp); 1H
NMR: δ 9.05 (s, 1H), 8.23 (d, J = 9.2 Hz, 1H), 8.12 (d, J =
9.2 Hz, 1H), 7.85 (s, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.47
(d, J = 8.4 Hz, 2H) ,7.03 (s, 1H), 6.18 (s, 2H), 4.23 (t, J =
6.4 Hz, 2H), 3.99 (s, 3H), 3.17 (s, 3H), 3.01 (t, J = 6.4 Hz,
2H), 2.47 (s, 3H); 13C NMR: δ 172.47, 156.95, 153.04,
150.28, 148.19, 145.48, 139.84, 138.45, 133.68, 132.14,
131.27, 129.59, 129.50, 128.03, 127.94, 126.38, 124.68,
122.63, 121.83, 108.37, 106.30, 102.57, 61.04, 57.46, 52.32,
26.63, 21.60; HRMS-ESI:m/z calcd 426.16998 C27H24NO4Cl
[M −Cl]+, found 462.16986.
8-(1-Naphthyl)protoberberine choride (6d)
Yield: 72%; Brown solid; mp 175–176°C; 1H NMR: δ 8.82
(s, 1H), 8.15−8.32 (m, 3H), 7.95−8.07 (m, 1H), 7.64−8.00
(m, 5H), 7.45−7.55 (m, 1H), 7.03 (s, 1H), 6.21 (s, 2H), 4.11
−4.30 (m, 2H), 4.10 (s, 3H), 3.98 (s, 3H), 2.90−3.05
(m, 2H); 13C NMR: δ 172.49, 156.87, 152.61, 150.73,
148.43, 145.38, 139.24, 136.72, 132.16, 131.87, 130.76,
130.08, 129.20, 128.26, 127.56, 126.01, 125.12, 124.39,
123.76, 121.65, 120.95, 108.39, 106.68, 106.29, 106.09,
102.69, 60.99, 57.91, 52.56, 26.81; HRMS-ESI: m/z calcd
462.16998 C30H24NO4Cl [M − Cl]
+, found 462.16996.
8-(n-Decyl)protoberberine chloride (6e)
Yield: 80%; Brown solid; mp 185–186°C; 1H NMR: δ
8.81 (s, 1H), 8.20 (d, J = 9.2 Hz, 1H), 8.02 (d, J = 9.2 Hz,
1H), 7.74 (s, 1H), 7.12 (s, 1H), 6.17 (s, 2H), 4.80 (t, J =
6.4 Hz, 2H), 4.03 (s, 3H), 4.05 (s, 3H), 3.16 (t, J = 6.4 Hz,
2H), 1.78 (t, J = 6.4 Hz, 2H), 1.27−1.58 (m, 16H), 0.87 (t,
J = 6.4 Hz, 3H); 13C NMR: δ 172.49, 161.58, 152.99,
150.09, 148.11, 146.08, 138.29, 133.10, 131.28, 125.66,
125.20, 121.92, 120.71, 108.19, 106.26, 102.48, 62.05,
57.52, 50.10, 32.77, 31.78, 29.83, 29.46, 29.22, 29.19,
28.40, 27.13, 22.58, 21.54, 14.45; HRMS-ESI: m/z calcd
476.27954 C30H38NO4Cl [M − Cl]
+, found 476.27971.
8-(p-Methoxy)phenylpseudoprotoberberine choride (7a)
Yield: 79%; Bright orange solid; mp 197–198°C; 1H NMR: δ
8.87 (s, 1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.66 (d, J = 8.4 Hz,
2H), 7.33 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.70 (s,1H), 6.19
(s, 2H), 4.34 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.92 (s, 3H),
3.71 (s, 3H), 3.04 (t, J = 6.4 Hz, 2H); 13C NMR: δ 161.47,
157.40, 155.03, 152.41, 150.32, 148.17, 139.55, 136.77,
131.66, 131.56, 131.39, 123.39, 122.89, 121.94, 119.24,
116.98, 115.36, 108.50, 106.94, 106.22, 106.13, 102.55,
57.23, 56.27, 55.99, 52.12, 26.82; HRMS-ESI: m/z calcd
442.16490 C27H24NO5Cl [M −Cl]
+, found 442.16488.
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Yield: 77%; Yellow solid; mp 224–225°C; 1H NMR: δ
8.90 (s, 1H), 7.80 (s, 1H), 7.67−7.71 (m, 2H), 7.30−7.35
(m, 2H), 7.26 (d, J = 6.4 Hz, 1H), 7.08 (s, 1H), 6.66
(s, 1H), 6.19 (s, 2H), 4.33 (t, J = 6.4 Hz, 2H), 4.09 (s,
3H), 3.85 (s, 3H), 3.70 (s, 3H), 3.06 (t, J = 6.4 Hz, 2H);
13C NMR: δ 160.14, 157.53, 154.44, 152.48, 150.37,
148.20, 139.48, 136.92, 132.26, 131.74, 131.34, 122.93,
121.79, 121.62, 119.33, 117.31, 115.15, 108.54, 106.72,
106.20, 106.08, 102.57, 57.25, 56.27, 55.99, 52.27, 26.78;




Yield: 78%; Yellow solid; mp 212–213°C; 1H NMR: δ 8.89
(s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 7.61 (d, J = 8.4 Hz, 2H),
7.58 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.65 (s, 1H), 6.19 (s,
2H), 4.31 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H), 3.69 (s, 3H), 3.05
(t, J = 6.4 Hz, 2H), 2.54 (s, 3H); 13C NMR: δ 157.44,
155.01, 152.43, 150.34, 146.65, 148.18, 141.42, 139.55,
136.85, 131.35, 130.50, 129.66, 128.20, 123.13, 121.87,
119.30, 108.51, 106.80, 106.21, 106.14, 102.56, 57.24,
56.25, 52.20, 26.78, 21.64, 21.52; HRMS-ESI: m/z calcd
426.16998 C27H24NO4Cl [M − Cl]
+, found 426.16986.
8-(p-Chloro)phenylpseudoprotoberberine chloride (7d)
Yield: 75%; Bright orange solid; mp 183–184°C; 1H NMR:
δ 8.91 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.87 (d, J = 8.0 Hz,
2H), 7.75−7.80 (m, 1H) 7.69 (s, 1H), 7.08 (s,1H), 6.60
(s, 1H), 6.19 (s, 2H), 4.30 (t, J = 6.4 Hz, 2H), 4.09 (s, 3H),
3.72 (s, 3H), 3.06 (t, J = 6.4 Hz, 2H); 13C NMR: δ 157.55,
153.59, 152.59, 150.41, 148.22, 139.64, 136.97, 134.87,
132.64, 131.83, 130.97, 130.20, 129.89, 126.50, 123.05,
121.76, 119.55, 108.56, 106.50, 106.22, 105.06, 102.60,
57.28, 56.39, 52.38, 26.76; HRMS-ESI: m/z calcd
446.11536 C26H21NO4Cl2 [M − Cl]
+, found 446.11483.
8-(m-Chloro)phenylpseudoprotoberberine chloride (7e)
Yield: 76%; Bright yellow solid; mp 179–180°C; 1H
NMR: δ 8.93 (s, 1H), 7.79−7.90 (m, 5H), 7.71 (s, 1H),
7.08 (s, 1H), 6.57 (s, 1H), 6.20 (s, 2H), 4.32 (t, J = 6.4 Hz,
2H), 4.09 (s, 3H), 3.71 (s, 3H), 3.07 (t, J = 6.4 Hz, 2H);
13C NMR: δ 157.58, 152.94, 152.63, 150.44, 148.23,
139.58, 137.05, 134.69, 132.96, 131.98, 131.74, 131.35,
129.59, 128.64, 123.00, 121.69, 119.63, 108.57, 106.40,
106.23, 106.14, 102.61, 57.31, 56.36, 52.46, 26.76; HRMS-




Yield: 72%; Yellow-brown solid; mp 198–200°C
(decomp); 1H NMR: δ 9.14 (s, 1H), 8.38 (d, J = 7.8 Hz,
1H), 8.22 (d, J = 7.8 Hz, 1H), 7.84−7.92 (m, 4H), 7.67
−7.71 (m, 1H), 7.51−7.55 (m, 1H), 7.40 (d, J = 8.2 Hz,1H), 7.05 (s, 1H), 6.34 (s, 1H), 6.20 (s, 2H), 4.20−4.32
(m, 2H), 4.10 (s, 3H), 3.43 (s, 3H), 2.93−3.05 (m, 2H);
13C NMR: δ 157.14, 152.66, 152.16, 149.89, 147.72,
139.79, 136.83, 133.09, 131.62, 130.90, 130.17, 129.01,
128.92, 128.36, 127.50, 127.35, 125.86, 124.42, 123.19,
121.54, 119.55, 108.07, 105.90, 105.80, 105.65, 102.12,
56.85, 55.65, 51.55, 26.40; HRMS-ESI: m/z calcd
462.17053 C30H24NO4Cl [M − Cl]
+, found 462.17072
(See Additional file 1).
8-(n-Decyl)pseudoprotoberberine chloride (7g)
Yield: 78%; Yellow-brown solid; mp 173–174°C; 1H NMR:
δ 8.67 (s, 1H), 7.68 (s, 2H), 7.11 (s, 1H), 6.37 (s, 1H), 6.17
(s, 2H), 4.77 (t, J = 6.4 Hz, 2H), 4.06 (s, 6H), 3.67 (t, J = 6.4
Hz, 2H,), 3.15 (t, J = 6.4 Hz, 2H), 1.24−1.16 (m, 16H), 0.85
(t, J = 4.0Hz, 3H); 13C NMR: δ 158.04, 157.19, 152.67,
150.12, 148.07, 139.33, 136.11, 131.31, 122.12, 122.02,
118.54, 108.31, 106.60, 106.21, 106.15, 102.49, 57.11,
56.94, 49.80, 31.77, 29.54, 29.45, 29.43, 29.26, 29.18 (2),
28.22, 27.17, 22.57, 14.44; HRMS-ESI: m/z calcd
476.28008 C30H38NO4Cl [M − Cl]
+, found 476.27990 (See
Additional file 1).
8-(n-Dodecyl)pseudoprotoberberine chloride (7h)
Yield: 80%; Bright yellow solid; mp 161–163°C (decomp);
1H NMR: δ 8.65 (s, 1H), 7.66 (s, 1H), 7.59 (s, 1H), 7.09
(s, 1H), 6.36 (s, 1H), 6.16 (s, 2H), 4.75(t, J = 6.4 Hz, 2H),
4.05 (s, 6H), 3.65 (t, J = 6.4 Hz, 2H,), 3.14 (t, J = 6.4 Hz,
2H), 1.20−1.74 (m, 20H), 0.84 (t, J = 4.0Hz, 3H); 13C
NMR: δ 158.12, 157.18, 152.67, 150.12, 148.07, 139.30,
136.09, 131.28, 122.09, 121.99, 118.50, 108.30, 106.57,
106.17, 106.12, 102.50, 57.10, 56.93, 49.79, 31.78, 29.53,
29.49, 29.42, 29.32, 29.25, 29.17, 29.14, 28.84, 28.21,
27.16, 22.58, 14.44; HRMS-ESI: m/z calcd 504.31084
C32H42NO4Cl [M − Cl]
+, found 504.31047.
8-(p-Methoxy)phenylprotopalmatine choride (8a)
Yield: 81%; Brown solid; mp 168–169°C; 1H NMR: δ
9.13 (s, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.14 (d, J = 9.2 Hz,
1H), 7.67 (s, 1H), 7.58 (d, J = 8.2 Hz, 2H), 7.23 (d, J =8.2
Hz, 2H), 7.04 (s, 1H), 4.29 (t, J = 6.4 Hz, 2H), 4.00 (s,
3H), 3.96 (s, 3H), 3.86 (s, 3H), 3.82 (s, 3H), 3.24 (s, 3H),
3.05 (t, J = 6.4 Hz, 2H); 13C NMR: δ 172.49, 160.74,
156.93, 152.77, 151.98, 149.36, 145.94, 139.98, 138.68,
133.77, 131.53, 129.72, 126.78, 124.63, 122.78, 121.49,
120.32, 113.38, 114.51, 111.29, 109.69, 61.32, 57.96,
56.81, 56.42, 55.87, 55.92, 26.37; HRMS-ESI: m/z calcd
458.19620 C28H28NO5Cl [M − Cl]
+, found 458.19613.
8-(m-Methoxy)phenylprotopalmatine choride (8b)
Yield: 78%; Red-brown solid; mp 170–171°C; 1H NMR: δ
9.15 (s, 1H), 8.25 (d, J = 9.2 Hz, 1H), 8.14 (d, J = 9.2 Hz,
1H), 7.76 (s, 1H), 7.56−7.60 (m, 1H), 7.20−7.26 (m, 3H),
7.05 (s, 1H), 4.29 (t, J = 6.4 Hz, 2H), 4.00 (s, 3H), 3.96 (s,
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6.4 Hz, 2H); 13C NMR: δ 165.70, 159.62, 156.25, 152.87,
152.04, 149.24, 145.37, 138.59, 136.24, 133.82, 130.42,
129.30, 126.42, 124.54, 122.36, 121.52, 120.10, 115.78,
113.73, 111.21, 109.66, 61.13, 57.42, 56.73, 56.34, 55.87,
52.49, 26.35; HRMS-ESI:m/z calcd 458.19619 C28H28NO5Cl
[M −Cl]+, found 458.19615.
8-(p-Methyl)phenylprotopalmatine choride (8c)
Yield: 74%; Yellow-brown solid; mp 164–165°C; 1H
NMR: δ 9.15 (s, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.15 (d, J =
9.2 Hz, 1H), 7.76 (s, 1H), 7.46−7.52 (m, 4H), 7.04 (s,
1H), 4.25 (t, J = 6.4 Hz, 2H), 4.00 (s, 3H), 3.96 (s, 3H),
3.86 (s, 3H), 3.18 (s, 3H), 3.03 (t, J = 6.4 Hz, 2H), 2.48 (s,
3H); 13C NMR: δ 172.49, 156.94, 152.89, 152.01, 149.22,
145.44, 139.80, 138.66, 133.78, 132.22, 129.51, 129.29,
128.00, 127.93, 126.38, 124.57, 122.56, 121.47, 120.26,
111.19, 109.67, 61.02, 57.43, 56.74, 56.34, 52.45, 26.32,
21.59; HRMS-ESI: m/z calcd 442.20128 C28H28NO4Cl
[M − Cl]+, found 442.20128.
8-(1-Naphthyl)protopalmatine choride (8d)
Yield: 78%; Yellow-brown solid; mp 177–178°C; 1H
NMR: δ 9.34 (s, 1H), 8.20−8.25 (m, 3H), 8.18 (d, J = 8.4
Hz, 1H), 7.84 (s, 1H), 7.76−7.80 (m, 2H), 7.63−7.67 (m,
1H), 7.47−7.49 (m, 2H), 7.02 (s, 1H), 4.13−4.35 (m, 2H),
3.99 (s, 3H), 3.94 (s, 3H), 3.85 (s, 3H), 2.93−3.05 (m,
2H), 2.77 (s, 3H); 13C NMR: δ 172.49, 155.06, 152.70,
152.07, 149.25, 144.94, 139.44, 134.03, 133.13, 132.42,
130.87, 130.58, 129.29, 128.21, 127.47, 126.59, 126.44,
126.00, 125.06, 124.74, 123.15, 122.16, 120.41, 111.19,
109.68, 60.78, 57.35, 56.78, 56.35, 52.40, 26.59; HRMS-




Yield: 75%; Brown solid; mp 172–173°C; 1H NMR: δ
8.90 (s, 1H), 8.20 (d, J = 9.2 Hz, 1H), 8.02 (d, J = 9.2 Hz,
1H), 7.65 (s, 1H), 7.13 (s, 1H), 4.83 (t, J = 6.4 Hz, 2H),
4.07 (s, 3H), 4.05 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.18
(t, J = 6.4 Hz, 2H), 1.79 (t, J = 6.4 Hz, 2H), 1.27−1.60 (m,
16H), 0.87 (t, J =6 .4Hz, 3H); 13C NMR: δ 176.25,
161.55, 152.84, 151.86, 149.18, 146.05, 138.49, 133.20,
129.31, 125.67, 125.08, 121.62, 120.35, 111.06, 109.62,
62.04, 57.50, 56.68, 56.36, 50.23, 32.77, 31.78, 29.84,
29.48, 29.46, 29.23, 29.19, 28.43, 26.84, 22.58, 14.45;




18 newly synthesized analogues were evaluated for their
activity against the multiplication of wild-type M. tuber-
culosis strain H37Rv and MRD strains by the microplate
alamar blue assay (MABA) at various concentrations of128.0, 64.0, 32.0, 16.0, 8.0, 4.0, 2.0, 1.0, 0.5, 0.25, 0.125,
and 0.0625 μg/ml. RIF and INH were used as positive
controls. Subsequent two-fold dilutions were performed
in 100 μL of 7H9 media in the 48-well microplates.
Then 100 μL of bacterial suspension was added to result
in a final bacterial titer of 1 × 106 CFU/mL. Plates were
incubated at 37°C. At optimal time, alamar blue solution
was added to the entire plate. Results were recorded at
24 h post-reagent addition. Visual MIC value was de-
fined as the lowest concentration of drug that prevented
a color change.
Cytotoxicity activity assay
African green monkey kidney (Vero) cells (6 × 103 cells/
well) and human lung fibroblast (MRC-5) cells (1.2 × 104
cells/well) were plated into a 96-well plates and incubated
37°C in 5% CO2. Sixteen hours later the cell cultures
were treated with various concentrations of compounds 7f
and 7g. Cytotoxicity was evaluated with the tetrazolium 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay at 48 h. The 50% cytotoxic concentration
(CC50) was calculated with Reed & Muench methods.
Each experiment was repeated three times.
Conclusion
In conclusion, 18 new 8-substituted BBR derivatives were
synthesized and evaluated for their antimycobacterial
activities against M. tuberculosis H37Rv. SAR analysis re-
vealed that (i) introduction of a n-decyl at the 8-position
might significantly enhance the activity; (ii) 10,11-
dimethoxy on the ring D might be beneficial for the
antimycobacterial activity. Among the test compounds,
compound 7g exhibited the strongest activity against both
drug-susceptible strains and MDR isolates of M. tubercu-
losis, suggesting a novel mechanism of action. It has been
selected as an ideal compound lead against TB for further
SAR investigation. We consider 8-n-decylberberines to be
a novel family of anti-tubercular agents with an advantage
of inhibiting MDR strains of M. tuberculosis.
Additional file
Additional file 1: Supporting information. Selected copies of
spectrum (1H-NMR, 13C-NMR and HRMS) for the two representative
compounds.
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